Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by E Dorman
Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Modelling the Effectiveness of Ibrutinib Versus Physician’s Choice (PC) in Relapsed or Refractory (RR) Waldenström’s Macroglobulinemia (WM) Within England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Comparison of the Appraisals by the English National Institute for Health and Care Excellence (NICE) for Two Therapies for Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL): Idelalisib+Rituximab (IR) and Ibrutinib
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
Current Hematologic Malignancy Reports
Cancer Research
Oncology
Hematology
Psy81 - Direct Costs Associated With the Treatment of Chronic Lymphocytic Leukemia (Cll) Relapsed or Refractory in Argentina
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Utility of Idelalisib in Combination With Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Safety and Efficacy of Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Transcend CLL 004: Minimal Residual Disease After Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
